A detergent, cleaning, fabric softener or cosmetic composition comprising a compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3,7-dimethyl-1,6-nonyldien represented by formula (I) ##STR00001##
is disclosed.

A compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 2-phenylpropyl represented by formula (I) ##STR00001##
is disclosed.

A compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 2-phenylpropyl represented by formula (I) ##STR00001##
is disclosed.

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X.sup.1 being S or X.sup.2 being S or O and at least one of X.sup.1 and X.sup.2 being S R.sup.2 H or C.sub.1-4-alkyl, R.sup.3 H or C.sub.1-4-alkyl R.sup.6 and R.sup.7 are hydrogen or together form a covalent carbon-carbon bond in general formula (a) R.sup.1 being H, C.sub.1-12-alkyl or CH.sub.2NR.sup.4R.sub.5 with R.sup.4 hydrogen or C.sub.1-4-alkyl, R.sup.5 C.sub.1-12-hydrocarbon residue which can contain one to three halogen atoms and/or one to four heteroatoms, selected from the group consisting of nitro-gen, oxygen and sulfur, it also being possible for R.sup.4 and R.sup.5, together with the nitrogen atom joining them, to form a 5- or 6-membered saturated or unsaturated heterocyclic radical, which optionally may also contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, in general formula (b) R.sup.1 being H or C.sub.1-17-hydrocarbon, preferably H, or CH.sub.2R.sup.5 with R.sup.5 being H or C.sub.1-16-hydrocarbon residue, which hydrocarbon can contain one to three halogen atoms and/or one to six heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur, and preferably in general formula (a) and (b) X.sup.1 and X.sup.2 being S, as nitrification inhibitor.

##STR00001##

The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X.sup.1 being S or X.sup.2 being S or O and at least one of X.sup.1 and X.sup.2 being S R.sup.2 H or C.sub.1-4-alkyl, R.sup.3 H or C.sub.1-4-alkyl R.sup.6 and R.sup.7 are hydrogen or together form a covalent carbon-carbon bond in general formula (a) R.sup.1 being H, C.sub.1-12-alkyl or CH.sub.2NR.sup.4R.sub.5 with R.sup.4 hydrogen or C.sub.1-4-alkyl, R.sup.5 C.sub.1-12-hydrocarbon residue which can contain one to three halogen atoms and/or one to four heteroatoms, selected from the group consisting of nitro-gen, oxygen and sulfur, it also being possible for R.sup.4 and R.sup.5, together with the nitrogen atom joining them, to form a 5- or 6-membered saturated or unsaturated heterocyclic radical, which optionally may also contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, in general formula (b) R.sup.1 being H or C.sub.1-17-hydrocarbon, preferably H, or CH.sub.2R.sup.5 with R.sup.5 being H or C.sub.1-16-hydrocarbon residue, which hydrocarbon can contain one to three halogen atoms and/or one to six heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur, and preferably in general formula (a) and (b) X.sup.1 and X.sup.2 being S, as nitrification inhibitor.

##STR00001##

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

A detergent, cleaning, fabric softener or cosmetic composition comprising a compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3,7-dimethyl-1,6-nonyldien represented by formula (I) ##STR00001##
is disclosed.